Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 70
Chinese Journal of Cardiology ; (12): 731-741, 2023.
Article in Chinese | WPRIM | ID: wpr-984711


Objective: For patients with atrial fibrillation (AF) complicated with acute coronary syndrome (ACS), both anticoagulant and antiplatelet therapy should be applied, but the use of anticoagulation therapy is still poor in these patients in China. The purpose of this study was to explore the status and adherence of antithrombotic therapy in AF patients with ACS and the impact on 1 year clinical outcomes. Methods: Patients with AF hospitalized for ACS were retrospectively included from 6 tertiary hospitals in China between July 2015 and December 2020. According to the use of anticoagulant drugs at discharge, patients were divided into two groups: anticoagulant treatment group and non-anticoagulant treatment group. Logistic regression model was used to analyze the main factors influencing the use of anticoagulant drugs in patients with atrial fibrillation complicated with ACS. Major adverse cardiac events (MACEs) were defined as all-cause death, non-fatal myocardial infarction or coronary revascularization, and ischemic stroke and Bleeding Academic Research Consortium (BARC) 3 bleeding events were also collected at 1 year after discharge. After propensity score matching, Cox proportional hazards models and Kaplan-Meier analysis were used to evaluate the effect of anticoagulant treatment and non-anticoagulant treatment on 1-year prognosis. The patients were divided into different groups according to whether anticoagulation was performed at discharge and follow-up, and the sensitivity of the results was analyzed. Results: A total of 664 patients were enrolled, and 273 (41.1%) were treated with anticoagulant therapy, of whom 84 (30.8%) received triple antithrombotic therapy, 91 (33.3%) received double antithrombotic therapy (single antiplatelet combined with anticoagulant), and 98 (35.9%) received single anticoagulant therapy. Three hundred and ninety-one (58.9%) patients were treated with antiplatelet therapy, including 253 (64.7%) with dual antiplatelet therapy and 138 (35.3%) with single antiplatelet therapy. After 1∶1 propensity score matching between the anticoagulant group and the non-anticoagulant group, a total of 218 pairs were matched. Multivariate logistic regression analysis showed that history of diabetes, HAS-BLED score≥3, and percutaneous coronary intervention were predictors of the absence of anticoagulant therapy, while history of ischemic stroke and persistent atrial fibrillation were predictors of anticoagulant therapy. At 1-year follow-up, 218 patients (79.9%) in the anticoagulant group continued to receive anticoagulant therapy, and 333 patients (85.2%) in the antiplatelet group continued to receive antiplatelet therapy. At 1-year follow-up, 36 MACEs events (13.2%) occurred in the anticoagulant group, and 81 MACEs events (20.7%) in the non-anticoagulant group. HR values and confidence intervals were calculated by Cox proportional risk model. Patients in the non-anticoagulant group faced a higher risk of MACEs (HR=1.802, 95%CI 1.112-2.921, P=0.017), and the risk of bleeding events was similar between the two group (HR=0.825,95%CI 0.397-1.715, P=0.607). Conclusions: History of diabetes, HAS-BLED score≥3, and percutaneous coronary intervention are independent factors for the absence of anticoagulant therapy in patients with AF complicated with ACS. The incidence of MACEs, death and myocardial infarction is lower in the anticoagulant group, and the incidence of bleeding events is similar between the two groups. The risk of bleeding and ischemia/thrombosis should be dynamically assessed during follow-up and antithrombotic regiments should be adjusted accordingly.

Humans , Atrial Fibrillation/drug therapy , Platelet Aggregation Inhibitors/adverse effects , Acute Coronary Syndrome/drug therapy , Fibrinolytic Agents/therapeutic use , Retrospective Studies , Treatment Outcome , Anticoagulants , Myocardial Infarction/complications , Hemorrhage , Percutaneous Coronary Intervention , Ischemic Stroke/drug therapy , Stroke
Chinese journal of integrative medicine ; (12): 655-664, 2023.
Article in English | WPRIM | ID: wpr-982306


Acute coronary syndrome (ACS) is one of the leading causes of death in cardiovascular disease. Percutaneous coronary intervention (PCI) is an important method for the treatment of coronary heart disease (CHD), and it has greatly reduced the mortality of ACS patients since its application. However, a series of new problems may occur after PCI, such as in-stent restenosis, no-reflow phenomenon, in-stent neoatherosclerosis, late stent thrombosis, myocardial ischemia-reperfusion injury, and malignant ventricular arrhythmias, which result in the occurrence of major adverse cardiac events (MACE) that seriously reduce the postoperative benefit for patients. The inflammatory response is a key mechanism of MACE after PCI. Therefore, examining effective anti-inflammatory therapies after PCI in patients with ACS is a current research focus to reduce the incidence of MACE. The pharmacological mechanism and clinical efficacy of routine Western medicine treatment for the anti-inflammatory treatment of CHD have been verified. Many Chinese medicine (CM) preparations have been widely used in the treatment of CHD. Basic and clinical studies showed that effectiveness of the combination of CM and Western medicine treatments in reducing incidence of MACE after PCI was better than Western medicine treatment alone. The current paper reviewed the potential mechanism of the inflammatory response and occurrence of MACE after PCI in patients with ACS and the research progress of combined Chinese and Western medicine treatments in reducing incidence of MACE. The results provide a theoretical basis for further research and clinical treatment.

Humans , Percutaneous Coronary Intervention/methods , Acute Coronary Syndrome/drug therapy , Coronary Disease , Treatment Outcome , Stents/adverse effects
In. Machado Rodríguez, Fernando; Liñares Divenuto, Norberto Jorge; Gorrasi Delgado, José Antonio; Terra Collares, Eduardo Daniel; Borba, Norberto. Traslado interhospitalario: pacientes graves y potencialmente graves. Montevideo, Cuadrado, 2023. p.103-126.
Monography in Spanish | LILACS, UY-BNMED, BNUY | ID: biblio-1523987
Chinese Journal of Cardiology ; (12): 1161-1168, 2022.
Article in Chinese | WPRIM | ID: wpr-969722


Objective: To assess low-density lipoprotein cholesterol (LDL-C) levels and use of lipid-lowering treatment among young and middle-aged ultra-high-risk patients with acute coronary syndrome (ACS) in China. Methods: The study was based on the"Improving Care for Cardiovascular Disease in China (CCC)-ACS"project, a collaborative registry by and Chinese Society of Cardiology (CSC) and the American Heart Association. Hospitalized-patients with ACS were consecutively enrolled from 159 tertiary and 82 secondary hospitals across China, related clinical information was collected. This study included young and middle-aged hospitalized patients (18-59 years) with ACS from November 2014 to December 2019 registered in CCC-ACS project. Ultra-high-risk was defined according to Chinese expert consensus on lipid management of ultra-high-risk atherosclerotic cardiovascular disease (ASCVD) patients of CSC. The mean LDL-C levels at admission, pre-hospital lipid-lowering therapy and proportion of patients with LDL-C target achieved were analyzed. Results: A total of 42 230 patients younger than 60 years with ACS were included in this study. The mean age was (50.4±6.9) years, and 86.8% (36 676/42 230) of the ACS patients were male. Among them, 86.9% (36 687/42 230) met the criteria of ultra-high-risk. The mean level of LDL-C at admission was (2.8±1.0)mmol/L, only 5.3 % (1 948/36 687) patients achieved the targeted goal of LDL-C<1.4 mmol/L. Among the ultra-high-risk ASCVD patients, 17.5% (6 430/36 687) received lipid-lowering drugs before hospitalization, 96.4% (6 198/6 430) of whom received statins monotherapy. Among patients receiving pre-hospital statins, only 9.9% (626/6 323) patients reached an LDL-C<1.4 mmol/L at admission. Conclusions: The majority of young and middle-aged hospitalized patients with ACS are ultra-high-risk patients for ASCVD in China. Pre-hospital lipid-lowering drugs use is lower in these ultra-high-risk ASCVD patients and most patients do not reach the new LDL-C target level at admission.

Middle Aged , Humans , Male , Adult , Female , United States , Cholesterol, LDL , Acute Coronary Syndrome/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , China , Atherosclerosis/drug therapy , Hypolipidemic Agents/therapeutic use
In. Soeiro, Alexandre de Matos; Leal, Tatiana de Carvalho Andreucci Torres; Accorsi, Tarso Augusto Duenhas; Gualandro, Danielle Menosi; Oliveira Junior, Múcio Tavares de; Caramelli, Bruno; Kalil Filho, Roberto. Manual da residência em cardiologia / Manual residence in cardiology. Santana de Parnaíba, Manole, 2 ed; 2022. p.830-834, tab.
Monography in Portuguese | LILACS | ID: biblio-1353529
Medicina (B.Aires) ; 81(5): 837-839, oct. 2021.
Article in Spanish | LILACS | ID: biblio-1351057


Resumen El ticagrelor es un antiagregante plaquetario que actúa a través de la unión reversible a los receptores P2Y12 de la adenosina-difosfato. En el síndrome coronario agudo, ha demostrado reducir el riesgo de eventos cardiovasculares mayores como infarto de miocardio, accidente cerebrovascular y muerte. Si bien se han descripto en detalle ciertas complicaciones hemorrágicas, renales, hepáticas y respiratorias por el uso del ticagrelor, otros efectos adversos menos frecuentes de la droga no han sido adecuadamente escla recidos. Presentamos el caso de un paciente con un síndrome de respuesta inflamatoria sistémica secundario al uso de ticagrelor.

Abstract Ticagrelor is anantiplatelet agent which acts through reversible binding to the P2Y12 adenosine-diphosphate recep tors. In acute coronary syndromes it has been shown to reduce the risk of major cardiovascular events such as myocardial infarction, stroke and death. Although some hemorrhagic, kidney, liver and respiratory complications have been described in detail with the use of ticagrelor, other less frequent adverse effects are not so well clari fied. We report the case of a patient with a systemic inflammatory response syndrome secondary to the use of ticagrelor.

Humans , Acute Coronary Syndrome/chemically induced , Acute Coronary Syndrome/drug therapy , Myocardial Infarction , Adenosine/adverse effects , Systemic Inflammatory Response Syndrome/chemically induced , Ticagrelor/adverse effects
Medicina (B.Aires) ; 81(1): 11-15, mar. 2021. graf
Article in Spanish | LILACS | ID: biblio-1287235


Resumen La adherencia al tratamiento médico farmacológico en pacientes que cursaron una hospitalización por un síndrome coronario agudo (SCA) es deficiente. El objetivo primario fue demostrar que, mediante la utilización de una aplicación digital para smartphones, se incrementa por lo menos un 30% la adherencia al tratamiento, en relación al grupo control, en pacientes con SCA. Se realizó un estudio unicéntrico aleatorizado, controlado, con distribución 1:1, simple ciego, que comparó la utilización de una aplicación para smartphones (grupo intervención), frente a la indicación de tratamiento farmacológico por escrito (grupo control), en términos de adherencia médica farmacológica total, en 90 pacientes que cursaron internación por un SCA. La adherencia fue determinada mediante el Cuestionario de Adherencia a la Medicación de Morisky. El paciente se consideró como "totalmente adherente" de obtener un puntaje perfecto (8/8 puntos). El período de seguimiento fue de 90 días posterior al egreso hospitalario. La edad promedio fue 63 ± 9 años, con el 76% de sexo masculino. El objetivo primario ocurrió en 67.4% (31/46) del grupo intervención vs. 20.5% (9/44) del grupo control (p < 0.001). En pacientes que cursaron una hospitalización por SCA, la utilización de una aplicación digital para smartphones incrementó la adherencia al tratamiento médico farmacológico.

Abstract Adherence to cardiovascular medications following acute coronary syndrome hospitalization is generally poor. The primary outcome was to demonstrate that the use of a digital application for smartphones increases the adherence to pharmacological treatment by 30 % in relation to the group without intervention, in patients with an acute coronary syndrome with or without ST segment elevation. In this unicentric, single blinded, randomized controlled trial with 1:1 allocation we compared the use of a digital application for smartphones and written information as standard of care, for the adherence to pharmacological treatment in 90 patients admitted to the hospital with an acute coronary syndrome. Adherence to medical treatment was measured by Morisky Medication Adherence Scale. A patient is considered to have good adherence when score is perfect (8 points). The follow up period was 90 days after hospital discharge. The mean age of the population was 63 ± 9 and 76% were male. At 90 days, 67.4% (31/46) of patients using the smartphone application were adherent compared with 20.5% (9/44) of patients in the control group (p < 0.001). In patients with acute coronary syndrome, the use of a smartphone application increased the medication adherence compared with the standard of care.

Humans , Male , Female , Acute Coronary Syndrome/drug therapy , Smartphone , Software , Medication Adherence , Secondary Prevention
Chinese Journal of Cardiology ; (12): 886-893, 2021.
Article in Chinese | WPRIM | ID: wpr-941372


Objective: To analyze the status of early use of oral β-blocker and its relationship with in-hospital outcomes in eligible patients with acute coronary syndrome (ACS). Methods: The study was based on the Improving Care for Cardiovascular Disease in China (CCC)-ACS project. The data of ACS patients that collected during 2014 to 2019 from 230 collaborating hospitals across China were analyzed. Propensity score matching method and Cox multivariate regression analysis were used to analyze the association between early use of oral β-blocker and in-hospital outcomes within 15 days. Results: A total of 38 663 eligible ACS patients were included in this study. The mean age was (57.0±9.0), and 78.8% of the ACS patients (30 470/38 663) were male. The proportion of early use of oral β-blockers was 64.9% (25 112/38 663), but varied substantially, in the 230 hospitals with a range from 0 to 100%. Compared with the patients no early use of oral β-blocker, the patients receiving early oral β-blocker had significantly lower incidence of major cardiovascular adverse events (MACEs) (3.4% (395/11 536) vs. 2.9%(339/11 536), P=0.036)and less occurrences of heart failure (2.7% (316/11 536) vs. 2.1% (248/11 536), P=0.004). Multivariate Cox regression analyses showed the patients receiving early oral β-blocker had 15.5%, 23.1%, and 35.3% lower risks of MACEs, heart failure and cardiogenic shock respectively than the patients no early oral β-blocker. Conclusions: Compared with the patients no early oral β-blocker, the patients receiving early oral β-blocker had lower risks of MACEs events, heart failure and cardiogenic shock. However, the early use of oral β-blocker in ACS patients was generally insufficient with huge differences among different hospitals in China.

Humans , Male , Acute Coronary Syndrome/drug therapy , Adrenergic beta-Antagonists/therapeutic use , Heart Failure , Hospitals , Shock, Cardiogenic
Chinese Journal of Cardiology ; (12): 143-149, 2021.
Article in Chinese | WPRIM | ID: wpr-941250


Objective: To explore the medication compliance for secondary prevention drugs and long-term prognosis of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) between hospitals in different regions of China. Methods: The Optimal Antiplatelet Therapy for Chinese Patients with Coronary Artery Disease (OPT-CAD) study was a prospective, multi-center and registered study. Patients diagnosed as ACS and underwent PCI in OPT-CAD study were selected. Taking the Yangtze River as the dividing line between the south and the north of China, these patients were divided into two groups according to the hospitals where the patients visited, namely the southerns region group (n=1 958) and the northerns region group (n=5 091). In order to reduce selection bias and potential confounding factors, the patients in the two groups were matched by the tendency score, and the patients in the two groups were matched by the 1: 1 nearest match method according to the tendency score. The main endpoint of this study was the major adverse cardiovascular and cerebrovascular events (MACCE) occurring within 5 years after discharge, namely the composite endpoint of cardiac death, myocardial infarction, and/or ischemic stroke. Secondary endpoints were all-cause death, cardiac death, myocardial infarction, ischemic stroke, and type 2, 3, and 5 bleeding events defined by the Academic Research Consortium on Hemorrhage (BARC) within 5 years. The secondary preventive drugs was recorded, including antiplatelet drugs, statins, beta blockers, angiotensin converting enzyme inhibitors/angiotensinⅡreceptor blockers (ACEI/ARB), etc. Before and after the matching, the secondary preventive medication and the incidence of clinical events of the two groups were compared. Results: A total of 7 049 ACS patients, including 1 958 patients in the southern region group and 5 091 patients in the northern region group were enrolled in this study. There were 5 319 males (37.9%), and the aged was (60.7±6.7) years. After propensity score matching, there were 1 324 cases in each group. Before matching, in the northern region group, the proportion of smoking, hypertension and diabetes, previous history (myocardial infarction, PCI and stroke) and family history of coronary heart disease were higher (all P<0.05). The proportion of complex lesions, diffuse lesions, small vessel lesions and thrombotic lesions in the northern region group was higher than that in the southern region group (all P<0.05). Sixty months after discharge, the antiplatelet patterns were quite different between patients in the northern and southern region group (P<0.001). The proportion of clopidogrel monotherapy in the southern region group was higher than that in the northern region group (9.8% (130/1324) vs. 1.1% (14/1324)), while the proportion of aspirin monotherapy in the northern region group was higher than that in the southern region group (67.4% (893/1324) vs. 46.5% (616/1324)). As for the use of other secondary prophylactic drugs, the proportion of patients in southern region group receiving beta blockers (24.5% (325/1324) vs. 16.8% (222/1324), P<0.001) and ACEI/ARB (19.4% (257/1324) vs. 10.0% (133/1324), P<0.001) was higher than that in northern region group. After matching, the incidence of MACCE (8.4%(111/1 324) vs.6.2% (82/1 324), P=0.030) and BARC 2, 3 and 5 bleeding (6.0% (80/1 324) vs. 4.0% (53/1 324), P=0.020) was higher in patients in northern region group. Conclusions: ACS patients who undergo PCI in northern area hospital is at higher prevalence of comorbidities and complicated coronary artery lesions compared to patients in the southern area hospital, and the drug compliance is worse than that in southern area, and the prognosis is also relatively poor.

Aged , Humans , Male , Middle Aged , Acute Coronary Syndrome/drug therapy , Angiotensin Receptor Antagonists , Angiotensin-Converting Enzyme Inhibitors , China , Medication Adherence , Percutaneous Coronary Intervention , Platelet Aggregation Inhibitors/therapeutic use , Prospective Studies , Secondary Prevention , Treatment Outcome
Arq. bras. cardiol ; 115(5): 830-839, nov. 2020. tab, graf
Article in Portuguese | SES-SP, LILACS | ID: biblio-1142260


Resumo Fundamentos: Poucos estudos discutiram causas para o subtratamento medicamentoso na SCA. Objetivos: Avaliar a não-administração e suspensão de medicamentos durante o tratamento intra-hospitalar da SCA na Estratégia de Registro de Síndrome Coronariana Aguda (estudo ERICO). Métodos: Analisamos prontuários de 563 participantes ERICO para avaliar a frequência e motivos da não administração e/ou suspensão de medicamentos. Construímos modelos de regressão logística para avaliar se sexo, idade ≥65 anos, nível educacional ou subtipo de SCA estavam associados com (a) não administração de ≥1 medicamentos; e (b) não administração ou suspensão de ≥1 medicamentos. O nível de significância foi 5%. Resultados: A amostra é composta por 58,1% de homens e com idade mediana de 62 anos. Em 183 (32,5%) participantes ≥1 medicamentos não foram administrados e 288 (51,2%) apresentaram ≥1 medicamentos não administrados ou suspensos. As causas mais frequentes foram risco de sangramento (aspirina, clopidogrel e heparina), insuficiência cardíaca (betabloqueadores) e hipotensão (inibidores da enzima conversora da angiotensina e bloqueadores dos receptores da angiotensina). Indivíduos com idade ≥65 anos (razão de chances [RC]:1,51; intervalo de confiança de 95% [IC95%]:1,05-2,19) e com angina instável (RC:1,72; IC95%:1,07-2,75) tiveram maior chance de não-administração. Considerando apenas pacientes com infarto do miocárdio, idade ≥65 anos foi associada tanto à não administração quanto à não administração ou suspensão. Conclusões: A não administração ou suspensão de ≥1 medicamento não foi rara no estudo ERICO. Indivíduos com idade ≥65 anos ou com angina instável tiveram maior chance de não administração e podem ser subtratados nesse cenário.

Abstract Background: Few studies have discussed the reasons for pharmacological undertreatment of Acute Coronary Syndrome (ACS). Objectives: To determine the frequency and reasons for the non-administration and suspension of medications during in-hospital treatments of ACS in the Strategy of Registry of Acute Coronary Syndrome (ERICO) study. Methods: The present study analyzed the medical charts of the 563 participants in the ERICO study to evaluate the frequency and reasons for the non-administration and/or suspension of medications. Logistic regression models were built to analyze if sex, age ≥65 years of age, educational level, or ACS subtype were associated with (a) the non-administration of ≥1 medications; and (b) the non-administration or suspension of ≥1 medications. The significance level was set at 5%. Results: This study's sample included 58.1% males, with a median of 62 years of age. In 183 (32.5%) participants, ≥1 medications were not administered, while in 288 (51.2%), ≥1 medications were not administered or were suspended. The most common reasons were the risk of bleeding (aspirin, clopidogrel, and heparin), heart failure (beta blockers), and hypotension (angiotensin-converting enzyme inhibitors and angiotensin receptor blockers). Individuals aged ≥65 (odds ratio [OR]:1.51; 95% confidence interval [95% CI]:1.05-2.19) and those with unstable angina (OR:1.72; 95% CI:1.07-2.75) showed a higher probability for the non-administration of ≥1 medication. Considering only patients with myocardial infarction, being ≥65 years of age was associated with both the non-administration and the non-administration or suspension of ≥1 medication. Conclusions: Non-administration or suspension of ≥1 medication proved to be common in this ERICO study. Individuals of ≥65 years of age or with unstable angina showed a higher probability of the non-administration of ≥1 medication and may be undertreated in this scenario. (Arq Bras Cardiol. 2020; 115(5):830-839)

Humans , Male , Female , Middle Aged , Pharmaceutical Preparations , Acute Coronary Syndrome/drug therapy , Angiotensin-Converting Enzyme Inhibitors , Platelet Aggregation Inhibitors , Aspirin , Clopidogrel
Chinese Journal of Cardiology ; (12): 1039-1046, 2020.
Article in Chinese | WPRIM | ID: wpr-941217


Objective: To assess the expanding needs on lipid-lowering treatment in patients with acute coronary syndrome (ACS) by applying newly issued definition of extreme high-risk, which is proposed by Chinese expert consensus on lipid management of extreme high-risk atherosclerotic cardiovascular disease (ASCVD) patients of Chinese Society of Cardiology (CSC). Methods: Data of this study was derived from the Improving Care for Cardiovascular Disease in China (CCC) project, which was a case-based nationwide registry study and launched as a collaborative initiative by the American Heart Association and the CSC. The project consecutively recruited ACS patients from158 tertiary hospitals and 82 second hospitals across China, and detailed clinical information of patients was collected. This study enrolled ACS inpatients in CCC project from November 2014 to July 2019. The proportion of extreme high-risk patients, their characteristics, mean LDL-C levels at admission, the gap between measured LDL-C level and the new target, and lipid-lowering therapy at discharge were assessed. Results: Among 104 516 ACS inpatients enrolled in this study, 75.1% (78 527/104 516) met the criteria of extreme high-risk and were expected to achieve the new LDL-C goal. Among patients at extreme high-risk, 21.2% (16 651/78 527) had multiple severe ASCVD events and 78.8% (61 876/78 527) had 1 severe ASCVD event and at least two high-risk factors. For the extreme high-risk patients, the mean level of LDL-C at admission was (2.8±1.0) mmol/L, prevalence of LDL-C ≥1.4 mmol/L was 93.4% (73 307/78 527) and the median gap between LDL-C level at admission and the target of 1.4 mmol/L was 1.3 (0.8, 2.0) mmol/L. If LDL-C could be further reduced to 50% of the admission level, we estimated that 55.6% (43 632/78 527) of the extreme high-risk patients would achieve the new LDL-C goal. Among 40 875 patients with information about discharge statin dosage, 93.5% (28 004/29 947) of the extreme high-risk patients were prescribed with statins at discharge, and among them 95.1% (26 632/28 004) received statin monotherapy and 91.1% (25 501/28 004) were at moderate doses of statins. Conclusion: About three fourth of inpatients with ACS were categorized as extreme high-risk based on the new definition of CSC expert consensuses, nine out of ten patients at extreme high-risk didn't achieve the new LDL-C target at admission, and the intensity of lipid-lowering therapy was insufficient in clinical practice. There are substantially expanding needs for implementing more intensive and effective lipid-lowering strategies.

Humans , Acute Coronary Syndrome/drug therapy , Asian People , Cardiology , China , Cholesterol, LDL , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Lipids , United States
Arq. bras. cardiol ; 113(3): 357-363, Sept. 2019. tab, graf
Article in English | LILACS | ID: biblio-1038556


Abstract Background: High platelet reactivity (HPR) during therapy with acetylsalicylic acid (ASA) is a poor prognostic factor in acute coronary syndromes (ACS). The prevalence of HPR during ACS is greater than that reported in stable diseases. However, it is unclear whether this prevalence of HPR is a transient phenomenon or a characteristic of this high-risk population. Objective: The main objective is to compare the effects of ASA on platelet function in the initial and late phases of ACS in a single population. Secondary objectives are: correlation between the tests between themselves and the relationship between the tests and the variation of the inflammatory markers (C-reactive protein and interleukin-6). Methods: Seventy patients with non-ST segment elevation (NSTE) ACS in use of 100-200 mg of ASA per day for at least 7 days were prospectively studied. Platelet function was assessed in the first 48 hours and subsequently after 3 months using four methods: VerifyNow™ (VFN), whole blood platelet aggregation (WBPA) with arachidonic acid (AA) and collagen as agonists, and platelet function analyzer (PFA). The level of statistical significance considered was < 0.05. Results: According to the more specific methods (WBPA with AA and VFN), the incidence of HPR was significantly higher in the early phase than in the late phase: WBPA with AA: 31% versus 13%, p = 0.015; VFN: 32% versus 16%, p = 0.049. The other methods tested, which were less specific for ASA, did not show significant differences between phases. The correlation between the methods was weak or moderate (r ranging from 0.3 to 0.5, p < 0.05), and there were no significant associations between HPR and inflammatory markers. Conclusion: The prevalence of HPR during AAS therapy, assessed by specific methods for cyclooxygenase 1 (COX-1), is higher during the acute phase than in the late phase of NSTE ACS.

Resumo Fundamento: A alta atividade plaquetária (AAP) durante a terapia com ácido acetilsalicílico (AAS) é fator de mau prognóstico nas síndromes coronarianas agudas (SCA). A prevalência de AAP durante a SCA é maior do que a relatada na doença estável. No entanto, não está claro se esta prevalência de AAP é um fenômeno transitório ou característica dessa população de alto risco. Objetivo: O objetivo principal é comparar, em uma mesma população, os efeitos do AAS sobre a função plaquetária nas fases inicial e tardia da SCA. Os objetivos secundários são: correlação entre os testes entre si e a relação entre os testes e a variação dos marcadores inflamatórios (proteína C reativa e interleucina-6). Métodos: Foram estudados prospectivamente 70 pacientes com SCA sem elevação de ST (SCSST) em uso de 100 a 200 mg de AAS por dia por pelo menos 7 dias. A função plaquetária foi avaliada nas primeiras 48 horas e 3 meses após por quatro métodos: VerifyNow™ (VFN), agregometria de sangue total (AST) com ácido araquidônico (AA) e colágeno como agonistas, e analisador de função plaquetária (PFA). O nível de significância estatístico considerado foi < 0,05. Resultados: A média de idade foi de 65 ±9,7 anos e 54% da população eram do sexo feminino. De acordo com os métodos mais específicos (AST com AA e VFN), a incidência de AAP foi significativamente maior na fase inicial, em relação à tardia: AST com AA 31% versus 13%, p = 0,015; VFN 32% versus 16%, p = 0,049. Os outros métodos testados, menos específicos para o AAS, não mostraram diferenças significativas entre as fases. A correlação entre os métodos foi fraca ou moderada (r variando de 0,3 a 0,5, p < 0,05), e não houve associações significativas entre AAP e marcadores inflamatórios. Conclusão: A prevalência de AAP durante a terapia com AAS, avaliada por métodos específicos para cicloxigenase 1 (COX-1), é maior durante a fase aguda do que na tardia da SCASST.

Humans , Male , Female , Middle Aged , Aged , Blood Platelets/drug effects , Platelet Aggregation Inhibitors/therapeutic use , Aspirin/therapeutic use , Acute Coronary Syndrome/drug therapy , Platelet Function Tests , Blood Platelet Disorders/drug therapy , Blood Platelets/metabolism , Platelet Aggregation Inhibitors/pharmacology , Aspirin/pharmacology , Prospective Studies , Risk Factors , Non-ST Elevated Myocardial Infarction/physiopathology
Rev. costarric. cardiol ; 21(1)ene.-jun. 2019.
Article in Spanish | LILACS, SaludCR | ID: biblio-1508115


Los medicamentos antiplaquetarios, representan el pilar del tratamiento farmacológico, en el síndrome coronario agudo. Su utilización pronta y precisa, permiten ganar minutos importantes en la toma de decisiones de estos pacientes, que permitan una resolución cabal y de optimo pronostico. Esta pequeña y práctica revisión pretende destacar las características más importantes de cada uno de ellos, que ofrezca al clínico optimizar la decisión del medicamento que representa la mejor estrategia terapéutica, en el contexto individual de cada paciente. Para esto se presentan de manera resumida los estudios más recientes que comparan los diferentes agentes, durante el síndrome coronario, que permitan un manejo más individualizado del paciente.

Antiplatelet drugs represent the main pharmacologic treatment on an acute coronary syndrome. Its fast, and precise utilization allow us gain important minutes on de decision making process of this patients, that allows a fast resolution with optimal prognosis. This practical small review pretends to pinpoint the most important characteristics of each one of this drugs that allows the clinician get the best decision on with drug offers the best therapeutic strategy on the individual context of the patient. So we present a summary of the latest trials that compare this agents on acute coronary syndrome that allows individualization o the patient management.

Humans , Platelet Aggregation Inhibitors/therapeutic use , Aspirin/therapeutic use , Acute Coronary Syndrome/drug therapy , Prasugrel Hydrochloride/therapeutic use , Clopidogrel/therapeutic use , Ticagrelor/therapeutic use
In. Consolim-Colombo, Fernanda M; Saraiva, José Francisco Kerr; Izar, Maria Cristina de Oliveira. Tratado de Cardiologia: SOCESP / Cardiology Treaty: SOCESP. São Paulo, Manole, 4ª; 2019. p.350-355.
Monography in Portuguese | LILACS | ID: biblio-1009348
Braz. j. med. biol. res ; 52(2): e8001, 2019. tab
Article in English | LILACS | ID: biblio-974279


There is no definite recommendation for testing platelet aggregation (PA) in acute coronary syndromes (ACS) due to inconclusive evidence on the usefulness of platelet function tests to guide therapy and improve clinical outcomes. The evaluation of PA with multiple electrode impedance platelet aggregometry (MEA) may be useful to manage antiplatelet therapy and possibly influence patient outcome. The primary aim of this study was to measure PA with MEA in Brazilian patients with ACS and evaluate the association between PA and adverse clinical outcomes. Forty-seven consecutive patients admitted with ACS to a Brazilian tertiary-care public hospital were studied and PA was evaluated using MEA. Patients were followed for six months for the occurrence of all-cause death, acute myocardial infarction, or stroke. Suboptimal inhibition of PA was found in 7 patients (14.9%); 5 (10.6%) in response to ASA (acetylsalicylic acid), 2 (5.0%) to clopidogrel, and none to ticagrelor. Inadequate PA inhibition in response to ASA was significantly associated with the composite end point, but there was no significant association for insufficient PA inhibition in response to clopidogrel. This study suggested that the evaluation of PA in ACS using MEA may identify non-responders to ASA. Larger studies are necessary to define, in a public health scenario, the value of MEA in the management of ACS.

Platelet Aggregation/drug effects , Electric Impedance/therapeutic use , Acute Coronary Syndrome/blood , Platelet Count , Platelet Function Tests , Platelet Aggregation Inhibitors/therapeutic use , Adenosine/therapeutic use , Pilot Projects , Aspirin/therapeutic use , Prospective Studies , Acute Coronary Syndrome/drug therapy , Receptors, Purinergic P2Y12/blood , Tertiary Care Centers , Hospitals, Public
Arch. Health Sci. (Online) ; 25(1): 10-10, 23/04/2018.
Article in Portuguese | LILACS | ID: biblio-1046563


Introdução: As interações entre fármaco e nutrientes podem acarretar reações adversas e/ou ineficácia da farmacoterapia ou provoca prejuízos no estado nutricional, sobretudo em idoso.Casuísitica e Metodos: Trata-se de um estudo descritivo exploratório com análise de 607 prescrições para idosos hospitalizados por Síndrome Coronariana Aguda, no período entre abril de julho de 2016, através das bases de dados Micromedexe Resultados: Foram identificadas e quantificadas 4.313 interações presentes nas prescrições, distribuídas entre 61 tipos de combinações entre os fármacos prescritos e nutrientes (macronutrientes, micronutrientes e frutas). Conclusão: Verifica-se alta taxa de interações entre fármacos e nutrientes nas prescrições para idosos com Síndrome Coronariana Aguda. Apesar do fato de que alguns nutrientes não sejam rotineiramente consumidos, é fundamental a revisão da prescrição e dos componentes da dieta pelo farmacêutico com objetivo de evitar problemas entre farmacoterapia e dieta dos pacientes.

Aged , Food-Drug Interactions/physiology , Acute Coronary Syndrome/drug therapy
Yonsei Medical Journal ; : 72-79, 2018.
Article in English | WPRIM | ID: wpr-742502


PURPOSE: This study sought to determine the 1-year clinical effectiveness and safety of a biodegradable, polymer-containing Biolimus A9™-eluting stent (BES) in Korean patients with acute coronary syndrome (ACS). MATERIALS AND METHODS: A total of 1000 ACS patients with 1251 lesions who underwent implantation of BESs at 22 centers in Korea were enrolled between May 2011 and July 2013. We assessed major adverse cardiac events (MACE) defined as the composite of cardiac death, non-fatal myocardial infarction (MI), and clinical-driven target vessel revascularization at 12 months. RESULTS: Patient mean age was 62.6±11.4 years. 72.8% of the patients were male, 28.5% had diabetes, 32.8% had multi-vessel disease (MVD), and 47.9% presented with acute MI (AMI). The mean global registry of acute coronary events risk score of all patients was 103.0±27.6. The number of stents per patient was 1.3±0.6. The incidences of MACE and definite stent thrombosis at 12 months were 3.9% and 0.2%, respectively. On multivariate Cox-regression analysis, age ≥65 years was identified as an independent predictors of 1-year MACE (hazard ratio=2.474; 95% confidence interval=1.202−5.091). Subgroup analyses revealed no significant differences in the incidence of MACE between patients with and without diabetes (4.3% vs. 3.7%, p=0.667), between those who presented with and without AMI (4.4% vs. 3.4%, p=0.403), and between those with and without MVD (4.6% vs. 3.5%, p=0.387). CONCLUSION: Our study demonstrated excellent 1-year clinical outcomes of BES implantation in patients at low-risk for ACS.

Aged , Female , Humans , Male , Middle Aged , Acute Coronary Syndrome/drug therapy , Drug-Eluting Stents/adverse effects , Incidence , Kaplan-Meier Estimate , Multivariate Analysis , Proportional Hazards Models , Republic of Korea , Sirolimus/adverse effects , Sirolimus/analogs & derivatives , Sirolimus/therapeutic use , Time Factors , Treatment Outcome
Arch. Health Sci. (Online) ; 24(4): 52-57, 22/12/2017.
Article in Portuguese | LILACS | ID: biblio-1046777


Introdução: As interações entre fármacos e nutrientes acarretam reações adversas e/ou ineficácia da farmacoterapia, além de provocar prejuízos no estado nutricional, sobretudo em idosos. Objetivo: Descrever a taxa de interações potenciais teóricas entre nutrientes da dieta e fármacos prescritos para idosos hospitalizados por Síndrome Coronariana Aguda em um hospital de ensino. Material e Métodos: Trata-se de um estudo transversal com delineamento descritivo e abordagem qualitativa que analisou 607 prescrições no período entre abril e julho de 2016, utilizando-se as bases de dados informatizadas Micromedex e Resultados: Foram identificadas 4.313 interações distribuídas em 61 tipos entre os fármacos prescritos e nutrientes. Conclusão: Verifica-se alta taxa de interações entre fármacos e nutrientes nas prescrições para idosos com Síndrome Coronariana Aguda. Apesar do fato de que alguns nutrientes não são rotineiramente consumidos, é fundamental a revisão da prescrição e dos componentes da dieta pelo farmacêutico para evitar problemas relacionados às interações.

Introduction: Food-drug interactions result in adverse reactions and/or ineffectiveness of pharmacotherapy. Furthermore, these interactions cause nutritional losses, especially in elderly people. Objective: Describe the rate of potential theoretical interactions between nutrients of dietary and drugs prescribed for elderly people hospitalized with Acute Coronary Syndrome in a teaching hospital. Material and Methods: This isa transversal, descriptive study using a qualitative approach. We analyzed 607 prescriptions from April to July 2016. We used databases such as Micromedex and Weidentified 4,313 interactions, which were distributed in 61 types between the prescribed drugs and food. Conclusion: There is a high rate of food-drug interactions in the prescriptions for the elderly people with Acute Coronary Syndrome. Despite the fact that some nutrients are not routinely consumed, it is very important the revision of the prescription and diet components by the pharmacist to avoid problems related to interactions.

Humans , Male , Female , Middle Aged , Aged , Aged , Food-Drug Interactions , Acute Coronary Syndrome/drug therapy , Prescriptions/statistics & numerical data , Hospitals, Teaching
Rev. eletrônica enferm ; 19: 1-12, Jan.Dez.2017. tab, ilus
Article in Portuguese | LILACS, BDENF | ID: biblio-911459


Objetivou-se determinar a taxa de interações medicamentosas potenciais teóricas em prescrições para idosos diagnosticados com Síndrome Coronariana Aguda em um hospital de ensino. Estudo descritivo exploratório com análise de 607 prescrições através de bases de dados informatizadas para identificar e classificar as interações de acordo com a intensidade (maior, moderada ou menor), mecanismo (farmacocinético ou farmacodinâmico) e relevância da documentação. Foram detectadas 10.162 interações, distribuídas entre 554 tipos de combinações diferentes dentre os medicamentos prescritos, e 99% das prescrições apresentaram pelo menos uma e máximo de 53 interações, destacando-se a prevalência de maiores e moderadas. Houve correlação entre o número de interações e o número de medicamentos prescritos e o tempo de hospitalização. Este estudo contribui para a delimitação do padrão de prevalência das interações medicamentosas em prescrições para Síndrome Coronariana Aguda, além de subsidiar a importância da implantação efetiva da Farmácia Clínica em hospitais de ensino.

The objective was to determine the rate of potential drug-drug interactions in prescriptions for elderly diagnosed with Acute Coronary Syndrome in a teaching hospital. This is an exploratory, descriptive study that analyzed 607 prescriptions through databases to identify and classify the interactions based on intensity (major, moderate or minor), the mechanism (pharmacokinetic or pharmacodynamics) and documentation relevance. We detected 10,162 drug-drug interactions, distributed in 554 types of different combinations within the prescribed drugs, and 99% of prescriptions presented at least one and a maximum of 53 interactions; highlighting the prevalence of major and moderates ones. There was a correlation between the number of drug-drug interactions and the number of prescribed drugs and the hospitalization time. This study contributes for the delimitation of a prevalence pattern in drug-drug interactions in prescriptions for Acute Coronary Syndrome, besides subsidizing the importance of the effective implementation of the Clinical Pharmacy in teaching hospitals.

Humans , Male , Female , Aged , Aged, 80 and over , Drug Prescriptions , Drug Interactions , Acute Coronary Syndrome/drug therapy , Hospitals, Teaching
Invest. clín ; 58(1): 79-92, mar. 2017. ilus, graf
Article in Spanish | LILACS | ID: biblio-841139


Las enfermedades tromboembólicas siguen siendo una de las causas más importantes de morbilidad y mortalidad en todo el mundo. El mecanismo fisiopatológico subyacente en los síndromes coronarios agudos es la trombosis coronaria. Por eso, la base de su tratamiento se ha centrado en los fármacos antiplaquetarios, fibrinolíticos y anticoagulantes. En un número importante de individuos deben emplearse medidas adicionales como, por ejemplo, el intervencionismo percutáneo coronario (angioplastia y la colocación de los llamados stentsintracoronarios). La aspirina se ha considerado como el fármaco de primera elección en la prevención de las afecciones tromboembólicas. La combinación aspirina-clopidogrel ha representado una terapéutica sumamente eficiente en el tratamiento de los eventos tromboembólicos. La introducción de tabletas de combinación fija representa un avance para facilitar el cumplimiento de la terapia.

Thromboembolic diseases remain one of the most important causes of morbidity and mortality worldwide. The pathophysiologic mechanism underlying the acute coronary syndromes is coronary thrombosis. That is why the basis of its treatment has focused on antiplatelet, fibrinolytic and anticoagulant drugs. In a significant number of individuals, additional measures must be used, such as, for example, the coronary percutaneous intervention (angioplasty and placement of the so-called intracoronary stents). Aspirin has been regarded as the drug of first choice in the prevention of thromboembolic diseases. The combination aspirin-clopidogrel has represented a highly efficient therapeutic measure for thromboembolic events. The introduction of fixed combination tablets represents a step forward in order to facilitate therapeutic compliance.

Humans , Ticlopidine/analogs & derivatives , Platelet Aggregation Inhibitors/administration & dosage , Aspirin/administration & dosage , Acute Coronary Syndrome/drug therapy , Fibrinolytic Agents/administration & dosage , Ticlopidine/administration & dosage , Drug Interactions , Drug Therapy, Combination , Clopidogrel